Evidence map›Paper›PMID 28075429›Full record

ArticleGene therapy2017

Telomerase-specific oncolytic adenovirus expressing TRAIL suppresses peritoneal dissemination of gastric cancer.

W Zhou, S Dai, H Zhu, Z Song, Y Cai, J B Lee, Z Li, X Hu, B Fang, C He and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Gene therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Genetic Modifications That Expand Oncolytic Virus Potency.Frontiers in molecular biosciences · 2022
    Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. The Effect of PEI-Mediated E1A on the Radiosensitivity of Hepatic Carcinoma Cells.Asian Pacific journal of cancer prevention : APJCP · 2020
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

W ZhouDepartment of Colorectal Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
S DaiDepartment of Colorectal Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
H ZhuDepartment of Colorectal Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Z SongDepartment of Colorectal Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Y CaiDepartment of Biochemistry and Molecular Medicine, The George Washington University Medical School, Washington, DC, USA.
J B LeeDepartment of Biochemistry and Molecular Medicine, The George Washington University Medical School, Washington, DC, USA.
Z LiDepartment of Biochemistry and Molecular Medicine, The George Washington University Medical School, Washington, DC, USA.
X HuKey Laboratory of Biotherapy of Zhejiang province, Hangzhou, China.
B FangDepartment of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
C HeDepartment of Colorectal Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
X HuangDepartment of Colorectal Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Zhejiang University · CNGeorge Washington University · USSir Run Run Shaw Hospital · CNThe University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peritoneal dissemination is the most common condition of metastasis in gastric cancer. The survival duration of a patient with advanced stage gastric cancer, may be improved by gene therapy. In this study, we used an oncolytic adenovirus vector (Ad/TRAIL-E1) that expresses both the TRAIL and E1A genes under the control of a tumor-specific promoter. We evaluated the anti-tumor effect of Ad/TRAIL-E1 on gastric cancer cells in vitro, as well as in vivo in a xenograft peritoneal carcinomatosis mouse model. Our data showed that Ad/TRAIL-E1 induced TRAIL-mediated apoptosis in gastric cancer cell lines, but not in the normal cell lines. In addition, Ad/TRAIL-E1 significantly inhibited peritoneal metastasis and prolonged the survival of mice without treatment-related toxicity. Therefore, tumor-specific TRAIL expression from an oncolytic adenovirus vector may provide a novel therapeutic approach for the treatment of advance stage gastric cancer with peritoneal dissemination.

Indexed as

AdenoviridaeAdenovirus E1A ProteinsAnimalsApoptosisCell Line, TumorCell ProliferationGene Expression Regulation, ViralGenetic VectorsHumansMiceOncolytic VirotherapyOncolytic VirusesPeritoneal NeoplasmsStomach NeoplasmsTelomeraseTNF-Related Apoptosis-Inducing LigandAdenovirus E1A ProteinsTelomeraseTNF-Related Apoptosis-Inducing LigandTNFSF10 protein, human

Identifiers

PMID28075429
OpenAlexW2571667415

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.